Cellect Bio’s ApoGraft stem cells completely accepted by first blood cancer patients in Phase 1/2 study; shares up … – Seeking Alpha
|
Cellect Bio's ApoGraft stem cells completely accepted by first blood cancer patients in Phase 1/2 study; shares up …
Seeking Alpha Thinly traded nano cap Cellect Biotechnology (NASDAQ:APOP) is up 86% premarket on robust volume in response to encouraging results in a Phase 1/2 clinical trial assessing ApoGraft-processed donor-derived peripheral blood cells transplanted into blood … Cellect (APOP) Says First Group of Patients in Clinical Trial With its ApoGraft Stem Cell Transplant Follow up … Cellect Biotechnology | $APOP Stock | Shares Surge On Positive Stem Cell Trial UPDATE: Cellect Biotech shares rocket 65% premarket after unveiling stem cell breakthrough |
